86 Ces Urol 2024; 28(2): 69–88 PŘEHLEDOVÉ ČLÁNKY 8. Amin MB, Menon S, Moch H. Tumours of the penis and scrotum. in: WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. 5th ed. IARC 2022; 372–379. 9. Michalová K, Beniač P, Kacerovská D. Tumor lesions of penis and scrotum according to WHO classifi‑ cation 2022. Cesk Patol. 2022; 67(4): 192–197. 10. Cubilla AL. The role of pathologic prognostic factors in squamous cell carcinoma of the penis. World J Urol. 2009; 27: 169–177. 11. Horenblas S, van Tinteren H. Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. J Urol. 1994; 151: 1239–1243. 12. Srinivas V, Morse MJ, Herr HW, et al. Penile cancer: relation of extent of nodal metastasis to survival. J Urol. 1987; 137: 880–881. 13. Clark PE, Spiess PE, Agarwal N, et al. National Comprehensive Cancer Network. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013; 11(5): 594–615. 14. Cubilla AL, Velazquez EF, Amin MB, et al. The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expert-driven recommendations. Histopathology. 2018; 72: 893–904. 15. Hrudka J, Prouzová Z, Kendall Bártů M, et al. Immune cell infiltration, tumour budding, and the p53 expression pattern are important predictors in penile squamous cell carcinoma: a retrospective study of 152 cases. Pathology. 2023; 55(5): 637–649. 16. Wen S, Ren W, Xue B, et al. Prognostic factors in patients with penile cancer after surgical management. World J Urol. 2018; 36(3): 435–440. 17. Naushad N, Deb AA, Agag AA, et al. Prognostic Markers and Trials in Penile Cancer. Urol Res Pract. 2023; 49(3): 138–146. 18. Guimarães GC, Cunha IW, Soares FA, et al. Penile squamous cell carcinoma clinicopathological fea‑ tures, nodal metastasis and outcome in 333 cases. J Urol. 2009; 182(2): 528–534. 19. Tang Y, Hu X, Wu K, Li X. Immune landscape and immunotherapy for penile cancer. Front Immunol 2022; 13: 1055235. 20. Wang Y, Wang K, Chen Y, et al. Mutational landscape of penile squamous cell carcinoma in a Chinese population. Int J Cancer. 2019; 145(5): 1280–1289. 21. Jacob JM, Ferry EK, Gay LM, et al. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. J Urol. 2019; 201(3): 541–548. 22. Zhou QH, Deng CZ, Li ZS, et al. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. Cell Death Dis. 2018; 9(6): 684. 23. Olesen TB, Sand FL, Rasmussen CL, et al. Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019; 20(1): 145–158. 24. May M, Burger M, Otto W, et al. Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis. BJU Int. 2013; 112(4): E383–390. 25. Senapati R, Senapati NN, Dwibedi B. Molecular mechanisms of HPV mediated neoplastic progression. Infect Agent Cancer. 2016; 11: 59. 26. Manfredi JJ. Mdm2 and MdmX: Partners in p53 Destruction. Cancer Res. 2021; 81(7): 1633–1634. 27. Buonerba C, Pagliuca M, Vitrone FM, et al. Immunotherapy for penile cancer. Future Sci OA. 2017; 3(3): FSO195.
RkJQdWJsaXNoZXIy NDA4Mjc=